JP2008537683A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008537683A5 JP2008537683A5 JP2008511104A JP2008511104A JP2008537683A5 JP 2008537683 A5 JP2008537683 A5 JP 2008537683A5 JP 2008511104 A JP2008511104 A JP 2008511104A JP 2008511104 A JP2008511104 A JP 2008511104A JP 2008537683 A5 JP2008537683 A5 JP 2008537683A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- seq
- sequence
- recombinant
- paramyxovirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091033319 polynucleotide Proteins 0.000 claims 29
- 102000040430 polynucleotide Human genes 0.000 claims 29
- 239000002157 polynucleotide Substances 0.000 claims 29
- 108090000623 proteins and genes Proteins 0.000 claims 19
- 150000007523 nucleic acids Chemical group 0.000 claims 17
- 102000039446 nucleic acids Human genes 0.000 claims 16
- 108020004707 nucleic acids Proteins 0.000 claims 16
- 239000002773 nucleotide Substances 0.000 claims 15
- 125000003729 nucleotide group Chemical group 0.000 claims 15
- 102000004169 proteins and genes Human genes 0.000 claims 15
- 238000006467 substitution reaction Methods 0.000 claims 15
- 230000035772 mutation Effects 0.000 claims 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims 13
- 229920001184 polypeptide Polymers 0.000 claims 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims 13
- 241001559187 Human rubulavirus 2 Species 0.000 claims 12
- 102100034574 P protein Human genes 0.000 claims 12
- 101710181008 P protein Proteins 0.000 claims 12
- 101710177166 Phosphoprotein Proteins 0.000 claims 12
- 239000013598 vector Substances 0.000 claims 10
- 208000015181 infectious disease Diseases 0.000 claims 7
- 230000002458 infectious effect Effects 0.000 claims 7
- 241000700605 Viruses Species 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 230000017156 mRNA modification Effects 0.000 claims 5
- 125000000539 amino acid group Chemical group 0.000 claims 4
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 claims 3
- 241000726041 Human respirovirus 1 Species 0.000 claims 3
- 101710141454 Nucleoprotein Proteins 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 230000000890 antigenic effect Effects 0.000 claims 3
- 230000037430 deletion Effects 0.000 claims 3
- 238000012217 deletion Methods 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000005026 transcription initiation Effects 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 108020004705 Codon Proteins 0.000 claims 2
- 241000712003 Human respirovirus 3 Species 0.000 claims 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine group Chemical group [C@@H]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C=NC=2C(N)=NC=NC12 OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 244000052769 pathogen Species 0.000 claims 2
- 230000006798 recombination Effects 0.000 claims 2
- 238000005215 recombination Methods 0.000 claims 2
- 102220111507 rs542840152 Human genes 0.000 claims 2
- 125000006850 spacer group Chemical group 0.000 claims 2
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 claims 1
- 241000710929 Alphavirus Species 0.000 claims 1
- 241000337692 Bunia Species 0.000 claims 1
- 235000013049 Bunias Nutrition 0.000 claims 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 1
- 241000711950 Filoviridae Species 0.000 claims 1
- 241000710831 Flavivirus Species 0.000 claims 1
- 101710133291 Hemagglutinin-neuraminidase Proteins 0.000 claims 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims 1
- 241000342334 Human metapneumovirus Species 0.000 claims 1
- 241000701806 Human papillomavirus Species 0.000 claims 1
- 241001559186 Human rubulavirus 4 Species 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 101710085938 Matrix protein Proteins 0.000 claims 1
- 201000005505 Measles Diseases 0.000 claims 1
- 241000712079 Measles morbillivirus Species 0.000 claims 1
- 101710127721 Membrane protein Proteins 0.000 claims 1
- 241000711386 Mumps virus Species 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims 1
- 241000711502 Paramyxovirinae Species 0.000 claims 1
- 241000711798 Rabies lyssavirus Species 0.000 claims 1
- 241000725643 Respiratory syncytial virus Species 0.000 claims 1
- 241000700584 Simplexvirus Species 0.000 claims 1
- 101150117115 V gene Proteins 0.000 claims 1
- 229960005305 adenosine Drugs 0.000 claims 1
- 230000002238 attenuated effect Effects 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 102200006537 rs121913529 Human genes 0.000 claims 1
- 102200006538 rs121913530 Human genes 0.000 claims 1
- 102220037638 rs4533 Human genes 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000005030 transcription termination Effects 0.000 claims 1
- 241000712461 unidentified influenza virus Species 0.000 claims 1
- 238000011144 upstream manufacturing Methods 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64331005P | 2005-01-12 | 2005-01-12 | |
| PCT/US2006/000666 WO2007120120A2 (en) | 2005-01-12 | 2006-01-10 | Attenuated human parainfluenza virus, methods and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008537683A JP2008537683A (ja) | 2008-09-25 |
| JP2008537683A5 true JP2008537683A5 (enExample) | 2009-02-26 |
Family
ID=38429996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008511104A Pending JP2008537683A (ja) | 2005-01-12 | 2006-01-10 | 減弱されたヒトパラインフルエンザウイルス、その方法および使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9034343B2 (enExample) |
| EP (1) | EP1877548B1 (enExample) |
| JP (1) | JP2008537683A (enExample) |
| AU (1) | AU2006332044A1 (enExample) |
| CA (1) | CA2605878A1 (enExample) |
| WO (1) | WO2007120120A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0909547A2 (pt) * | 2008-05-26 | 2019-03-06 | Cadila Healthcare Ltd. | vacina combinada de sarampo - hpv, vetor e hospedero |
| JP5807917B2 (ja) * | 2011-02-08 | 2015-11-10 | 国立大学法人三重大学 | 遺伝子導入用ウイルスベクターの製造方法 |
| CL2013002829A1 (es) | 2013-10-01 | 2014-04-04 | Univ Pontificia Catolica Chile | Formulacion inmunogenica que contiene bcg vivas recombinantes que expresan antigenos de metapneumovirus (hmpv) en una suspension que se prepara a partir de un liofilizado sin la necesidad de adjuvante; su uso farmaceutico; vacuna contra hmpv. |
| EP3247388B1 (en) | 2015-01-20 | 2025-09-10 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Recombinant human/bovine parainfluenza virus 3 (b/hpiv3) expressing a chimeric rsv/bpiv3 f protein and uses thereof |
| EP3601617B3 (en) | 2017-03-24 | 2024-03-20 | Gen-Probe Incorporated | Compositions and methods for detecting or quantifying parainfluenza virus |
| CN113462656B (zh) * | 2021-03-24 | 2022-09-30 | 兰州生物制品研究所有限责任公司 | 一种人三型副流感病毒冷适应温度敏感株及其应用 |
| CN113999292B (zh) * | 2021-10-27 | 2023-05-26 | 中国农业大学 | 靶向呼吸道病毒属病毒的多肽抑制剂 |
| CN121379992A (zh) * | 2025-10-27 | 2026-01-23 | 榆林学院 | 一种牛副流感病毒3型v蛋白缺失毒株及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69419913T2 (de) | 1993-05-14 | 2000-02-17 | Orbital Engine Co. (Australia) Pty. Ltd., Balcatta | Induktionssystem einer internen brennkraftmaschine |
| US20030082209A1 (en) * | 2000-07-05 | 2003-05-01 | Skiadopoulos Mario H. | Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines |
| US6764685B1 (en) * | 2000-03-21 | 2004-07-20 | Medimmune Vaccines, Inc. | Recombinant parainfluenza virus expression systems and vaccines |
| US7820181B2 (en) * | 2002-09-18 | 2010-10-26 | The United States Of America As Represented By The Department Of Health And Human Services | Recovery of recombinant human parainfluenza virus type 2 (HPIV2) from cDNA and use of recombinant HPIV2 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens |
-
2006
- 2006-01-10 JP JP2008511104A patent/JP2008537683A/ja active Pending
- 2006-01-10 WO PCT/US2006/000666 patent/WO2007120120A2/en not_active Ceased
- 2006-01-10 CA CA002605878A patent/CA2605878A1/en not_active Abandoned
- 2006-01-10 EP EP06850427.3A patent/EP1877548B1/en not_active Expired - Lifetime
- 2006-01-10 AU AU2006332044A patent/AU2006332044A1/en not_active Abandoned
- 2006-01-10 US US13/501,447 patent/US9034343B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Beaty et al. | Efficient and robust Paramyxoviridae reverse genetics systems | |
| Durbin et al. | Recovery of infectious human parainfluenza virus type 3 from cDNA | |
| Baron et al. | Rescue of rinderpest virus from cloned cDNA | |
| KR100885325B1 (ko) | 변형된 모빌리바이러스 ｖ 단백질 | |
| Buchholz et al. | Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter | |
| US5716821A (en) | Prevention and treatment of respiratory tract disease | |
| US5789229A (en) | Stranded RNA virus particles | |
| Radecke et al. | Reverse genetics meets the nonsegmented negative-strand RNA viruses | |
| KR101020532B1 (ko) | ｃＤＮＡ로부터의 비분절 네가티브 쇄 ＲＮＡ 바이러스의 회수를 위한 개선된 방법 | |
| Skiadopoulos et al. | Identification of mutations contributing to the temperature-sensitive, cold-adapted, and attenuation phenotypes of the live-attenuated cold-passage 45 (cp 45) human parainfluenza virus 3 candidate vaccine | |
| JP2003516148A5 (enExample) | ||
| EP1456398B1 (en) | Recovery of recombinant human parainfluenza virus type 1 (hpivi) from cdna | |
| Newman et al. | Sequence analysis of the Washington/1964 strain of human parainfluenza virus type 1 (HPIV1) and recovery and characterization of wild-type recombinant HPIV1 produced by reverse genetics | |
| Takeuchi et al. | Recombinant wild-type and Edmonston strain measles viruses bearing heterologous H proteins: role of H protein in cell fusion and host cell specificity | |
| JP2011507514A5 (enExample) | ||
| Bailly et al. | A recombinant human parainfluenza virus type 3 (PIV3) in which the nucleocapsid N protein has been replaced by that of bovine PIV3 is attenuated in primates | |
| JP6087908B2 (ja) | 組換えタンパク質および組換えウイルスを作製するための単純な２プラスミド哺乳動物発現系 | |
| Collins et al. | Support plasmids and support proteins required for recovery of recombinant respiratory syncytial virus | |
| US20160120974A1 (en) | Semi-live respiratory syncytial virus vaccine | |
| Komase et al. | The phosphoprotein of attenuated measles AIK-C vaccine strain contributes to its temperature-sensitive phenotype | |
| Skiadopoulos et al. | Attenuation of the recombinant human parainfluenza virus type 3 cp45 candidate vaccine virus is augmented by importation of the respiratory syncytial virus cpts530 L polymerase mutation | |
| Nolan et al. | Live-attenuated intranasal parainfluenza virus type 2 vaccine candidates developed by reverse genetics containing L polymerase protein mutations imported from heterologous paramyxoviruses | |
| JP2020522249A5 (enExample) | ||
| Samal | Paramyxoviruses as vaccine vectors | |
| AU2006332044A1 (en) | Attenuated human parainfluenza virus, methods and uses thereof |